

Sustainability Accounting Standards Board (SASB)

Health Care Sector & Biotechnology and Pharmaceuticals Industry

At BeyondSpring, we strive to be transparent with our stakeholders and provide useful disclosures to our investors. We do this to demonstrate our commitment to being accountable for how we operate. At this time, our product is still under development, therefore most of the SASB metrics or topics do not currently apply to our business as they are developed for companies with commercialized products (marked N/A). We will continue to evolve and grow to be leaders in the space of ESG disclosure.

Data and information disclosed are sourced from BeyondSpring Form 20-F and from our web disclosures. We are working on closing existing data gaps as our business matures.

Overview of our assessment of BeyondSpring's alignment with SASB (updated May 2024)

Code	Accounting Metric	Response / Reference
SAFETY OF CLINICAL TRIAL PARTICIPANTS		
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	N/A. We and our Contract Research Organizations are required to comply with Good Clinical Practice requirements, which are regulations and guidelines enforced by the FDA, NMPA, EMA and other comparable regulatory authorities for all drugs in clinical development.
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	Zero.
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Zero. 2023 20-F Legal Proceedings (F-26, P236)
ACCESS TO MEDICINES		
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	N/A. Our drug is not commercialized.
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	N/A. Our drug is not commercialized.

Code	Accounting Metric	Response / Reference
AFFORDABILITY & PRICING		
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	N/A. Our drug is not commercialized.
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	N/A. Our drug is not commercialized.
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	N/A. Our drug is not commercialized.
DRUG SAFETY		
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	N/A. Our drug is not commercialized.
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	N/A. Our drug is not commercialized.
HC-BP-250a.3	Number of recalls issued, total units recalled	N/A. Our drug is not commercialized.
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	N/A. Our drug is not commercialized.
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	Zero. 2023 20-F Good Manufacturing Practice (P106), Manufacturing & Supply (P120)
COUNTERFEIT DRUGS		
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	N/A. Our drug is not commercialized.
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	N/A. Our drug is not commercialized.
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	N/A. Our drug is not commercialized.

Code	Accounting Metric	Response / Reference
ETHICAL MARKETING		
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Zero. 2023 20-F Legal Proceedings (F-26, P236)
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	N/A. Our drug is not commercialized.
EMPLOYEE RECRUITMENT, DEVELOPMENT & RETENTION		
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	2023 20-F Human Capital Resources (P148)
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	We do not report.
SUPPLY CHAIN MANAGEMENT		
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	We do not report.
BUSINESS ETHICS		
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Zero. 2023 20-F Legal Proceedings (F-26, P236)
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	Code of Ethics and Business Conduct (PP4,5)
ACTIVITY		
HC-BP-000.A	Number of patients treated	N/A. Our drug is not commercialized.
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	2023 20-F Our Pipeline (P85)